Suppr超能文献

经导管二尖瓣缘对缘修复术:MiCLASP 研究的 1 年结果。

Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study.

机构信息

Department of Cardiology, University Medical Center Mainz, Mainz, Germany.

Contilia Herz- und Gefäßzentrum, Elisabeth-Krankenhaus Essen, Nordrhine Westfalia, Germany.

出版信息

JACC Cardiovasc Interv. 2024 Apr 8;17(7):890-903. doi: 10.1016/j.jcin.2024.02.022.

Abstract

BACKGROUND

Mitral transcatheter edge-to-edge repair (M-TEER) is a guideline-recommended treatment option for patients with severe symptomatic mitral regurgitation (MR). Outcomes with the PASCAL system in a post-market setting have not been established.

OBJECTIVES

The authors report 30-day and 1-year outcomes from the MiCLASP (Transcatheter Repair of Mitral Regurgitation with Edwards PASCAL Transcatheter Valve Repair System) European post-market clinical follow-up study.

METHODS

Patients with symptomatic, clinically significant MR were prospectively enrolled. The primary safety endpoint was clinical events committee-adjudicated 30-day composite major adverse event rate and the primary effectiveness endpoint was echocardiographic core laboratory-assessed MR severity at discharge compared with baseline. Clinical, echocardiographic, functional, and quality-of-life outcomes were assessed at 1 year.

RESULTS

A total of 544 patients were enrolled (59% functional MR, 30% degenerative MR). The 30-day composite major adverse event rate was 6.8%. MR reduction was significant from baseline to discharge and sustained at 1 year with 98% of patients achieving MR ≤2+ and 82.6% MR ≤1+ (all P < 0.001 vs baseline). One-year Kaplan-Meier estimate for survival was 87.3%, and freedom from heart failure hospitalization was 84.3%. Significant functional and quality-of-life improvements were observed at 1 year, including 71.6% in NYHA functional class I/II, 14.4-point increase in Kansas City Cardiomyopathy Questionnaire score, and 24.2-m improvement in 6-minute walk distance (all P < 0.001 vs baseline).

CONCLUSIONS

One-year outcomes of this large cohort from the MiCLASP study demonstrate continued safety and effectiveness of M-TEER with the PASCAL system in a post-market setting. Results demonstrate high survival and freedom from heart failure hospitalization, significant and sustained MR reduction, and improvements in symptoms, functional capacity, and quality of life.

摘要

背景

二尖瓣经导管缘对缘修复术(M-TEER)是指南推荐的严重症状性二尖瓣反流(MR)患者的治疗选择。在上市后环境中,PASCAL 系统的结果尚未确定。

目的

作者报告了经导管二尖瓣反流修复术用爱德华兹 PASCAL 经导管瓣膜修复系统(PASCAL 系统)的 MiCLASP(经导管修复二尖瓣反流)欧洲上市后临床随访研究的 30 天和 1 年结果。

方法

前瞻性纳入有症状、临床上显著的 MR 患者。主要安全性终点是临床事件委员会裁定的 30 天复合主要不良事件发生率,主要有效性终点是超声心动图核心实验室评估的出院时与基线相比的 MR 严重程度。在 1 年时评估临床、超声心动图、功能和生活质量结果。

结果

共纳入 544 例患者(功能性 MR 占 59%,退行性 MR 占 30%)。30 天复合主要不良事件发生率为 6.8%。从基线到出院,MR 减少具有显著意义,且在 1 年时持续,98%的患者实现了 MR≤2+,82.6%的患者实现了 MR≤1+(均 P<0.001 与基线相比)。1 年的 Kaplan-Meier 生存估计为 87.3%,心力衰竭住院无事件生存率为 84.3%。在 1 年时观察到显著的功能和生活质量改善,包括纽约心脏病协会(NYHA)心功能分级 I/II 级的患者比例增加了 71.6%,堪萨斯城心肌病问卷评分增加了 14.4 分,6 分钟步行距离增加了 24.2 米(均 P<0.001 与基线相比)。

结论

MiCLASP 研究中来自该大型队列的 1 年结果表明,在上市后环境中,PASCAL 系统的 M-TEER 具有持续的安全性和有效性。结果表明,生存率高,心力衰竭住院无事件率高,MR 显著且持续减少,症状、功能能力和生活质量得到改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验